International meeting on cancer vaccines: How can we enhance efficacy of therapeutic vaccines?

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6827-6830

  Belardelli, Filippo ^a   Ferrantini, Maria ^a   Parmiani, Giorgio ^b   Schlom, Jeffrey ^c   Garaci, Enrico ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CANCER VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 PROTEIN P185 MAJOR HISTOCOMAPATIBILITY ANTIGEN CLASS 1 FUSION PROTEIN; FOWLPOX NY ESO 1 VACCINE; GENE PRODUCT; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEPATITIS B VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN 3; MELANOMA PEPTIDE; PROSTAGLANDIN E2; PROTEIN P185; RECOMBINANT VACCINE; RECOMBINANT VACCINIA VACCINE; THYMOSIN ALPHA1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; VACCINIA; VIRUS RECOMBINANT;

CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 4644253363     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2048     Document Type: Conference Paper

References (0)